Skip to content
Peptide research

AHK-Cu

Also known as Copper Tripeptide-3
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

AHK-Cu is a copper-binding peptide marketed for hair regrowth and skin support, said to activate the dermal papilla and support collagen. The evidence is almost entirely cell-culture and mechanism work; there are no controlled human trials, so the human case is weak. Safety data is thin, and it is contraindicated in Wilson disease, Menkes disease, and copper allergy. It is not an approved drug; it is sold in cosmetics subject to FDA cosmetic requirements and as unregulated products sold online.

Read Full record

Studied uses & evidence

Studied uses(12)

  • Stimulates hair follicle elongation and extends the anagen (active growth) phase

    Speculative

    Single ex vivo human follicle study measured elongation; anagen-phase extension is inferred, not directly shown.

  • Promotes dermal papilla cell proliferation at picomolar to nanomolar concentrations

    Speculative

    Dose-dependent effect shown in cultured human dermal papilla cells in one 2007 study, never replicated.

  • Anti-apoptotic effects: increases Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARP

    Low

    Shown in vitro/ex vivo: AHK-Cu raised Bcl-2/Bax and lowered cleaved caspase-3, PARP in human dermal papilla cells.

Evidence limits

Evidence Level
Preclinical

The primary evidence comes from the Pyo et al. (2007) study at Seoul National University, which demonstrated AHK-Cu stimulates hair follicle elongation ex vivo and DPC proliferation in vitro using human tissue. The study employed rigorous methods including flow cytometry and Western blotting. Additional supportive evidence comes from the broader copper peptide literature, particularly the extensive GHK-Cu research base. The tripeptide class has been validated in multiple wound healing and skin regeneration studies.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(12)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Limited long-term safety data — most studies are short-duration in vitro experiments

    High
  • Contraindicated in Wilson disease (copper metabolism disorder) and Menkes disease

    Moderate
  • Contraindicated in individuals with copper allergies

    Moderate
  • Insufficient safety data for use during pregnancy and breastfeeding — avoid as precaution

    Moderate
  • Local skin irritation (redness, itching) at application site — generally mild and transient

    Low
  • Should not be applied to broken, infected, or actively inflamed skin

    Low
  • Short in vivo half-life (<30 minutes in plasma) limits systemic bioavailability

    Theoretical
  • Rapid enzymatic degradation by proteases may reduce efficacy without proper formulation

    Low
  • Potential for allergic/hypersensitivity reactions (rare)

    Low
  • Potential copper toxicity if combined with oral copper supplements — monitor total copper intake

    Theoretical
  • Temporary increased hair shedding in first 4-6 weeks of use (adjustment period)

    Theoretical
  • Metallic taste or nausea reported rarely — discontinue if persistent

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.